With only 10 to 30 grams of Sovaldi needed for successful treatment, the difference from the $30 production cost
for Gilead’s full course of treatment—30 grams x $1.00 per
gram—to $84,000 for the 12-week treatment program represents a retail markup of 279,000%.)
Weinstein’s letter to state Medicaid directors also reminds them that, “Gilead did not pay to research and develop Sovaldi. In 2011, it purchased Pharmasset, the company that had already developed the drug, for $11 billion in cash.